Status:
COMPLETED
Treatment of Wegener's Granulomatosis With Cyclophosphamide
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Vasculitis
Wegener's Granulomatosis
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
The purpose of this protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate t...
Detailed Description
The purpose of the protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate th...
Eligibility Criteria
Patients greater than 1 year of age with the clinical and pathological diagnosis of WG whose illness presents a risk of permanent disability or death. Examples of processes that impart risk of permanent disability or death include: peripheral and central nervous system disease, cardiac involvement, glomerulonephritis, and vascular comprise of gastrointestinal organs.
No women who are pregnant or intend to become pregnant.
No patients who have known malignancies.
Patients must be HIV negative.
Key Trial Info
Start Date :
February 1 1976
Trial Type :
INTERVENTIONAL
End Date :
February 1 2002
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00001155
Start Date
February 1 1976
End Date
February 1 2002
Last Update
March 4 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, United States, 20892